(PharmaNewsWire.Com, June 09, 2017 ) Degenerative disc disease is refers to degeneration of intervertebral discs of the spinal column. The main symptom of degenerative disc disease is pain, which often worsens during certain types of activity. Predisposing factors include aging and injury or trauma. Treatment includes non-steroidal anti-inflammatory drugs, muscle relaxants, pain relievers and antidepressants.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Degenerative Disc Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Degenerative Disc Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 1, 1, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Degenerative Disc Disease (Musculoskeletal Disorders). - The pipeline guide reviews pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Degenerative Disc Disease (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
AnGes MG Inc Biogenomics Ltd Biopharm GmbH BioRestorative Therapies Inc Bone Therapeutics SA DiscGenics Inc ISTO Technologies Inc Osiris Therapeutics Inc Samumed LLC TissueGene Inc U.S. Stem Cell Inc Yuhan Corp
Number of Products under Development for Degenerative Disc Disease, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Degenerative Disc Disease - Pipeline by AnGes MG Inc, H1 2017 Degenerative Disc Disease - Pipeline by Biogenomics Ltd, H1 2017 Degenerative Disc Disease - Pipeline by Biopharm GmbH, H1 2017 Degenerative Disc Disease - Pipeline by BioRestorative Therapies Inc, H1 2017 Degenerative Disc Disease - Pipeline by Bone Therapeutics SA, H1 2017 Degenerative Disc Disease - Pipeline by DiscGenics Inc, H1 2017 Degenerative Disc Disease - Pipeline by ISTO Technologies Inc, H1 2017 Degenerative Disc Disease - Pipeline by Osiris Therapeutics Inc, H1 2017 Degenerative Disc Disease - Pipeline by Samumed LLC, H1 2017 Degenerative Disc Disease - Pipeline by TissueGene Inc, H1 2017 Degenerative Disc Disease - Pipeline by U.S. Stem Cell Inc, H1 2017 Degenerative Disc Disease - Pipeline by Yuhan Corp, H1 2017 Degenerative Disc Disease - Dormant Projects, H1 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
